LAVAL, QC, Sept. 5, 2018 /CNW Telbec/ - Servier Group announced August 31st, the closing of the global acquisition of Shire's oncology branch following final clearance by the regulatory authorities. As a result of this transaction, Servier Canada strengthened its oncology portfolio with two marketed products. ONCASPARTM (pegaspargase) is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukaemia (ALL) and ONIVYDETM (irinotecan liposome) is a topoisomerase inhibitor indicated for metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have disease progression following gemcitabine-based therapy.
"We established our Oncology Business Unit in Canada two years ago, as a result of a global strategic orientation. In this short period of time, we have consolidated our canadian portfolio in both solid tumors and hemato-malignancies and this recent acquisition is a major step forward", underlined Frederic Fasano, Chief Executive Officer of Servier Canada Inc.
Servier Canada's current portfolio comprises products soon to be marketed. ZEVALIN® is the only single-course chemo-free treatment regimen approved by Health Canada for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin's lymphoma, including patients with rituximab-refractory follicular non-Hodgkin's lymphoma. FOLOTYN® and BELEODAQ® are currently under review by Health Canada as anti-neoplastic agents in relapsed or refractory peripheral T-cell lymphoma.
"Servier Canada's commitment is to bring innovative treatment options to Canadian patients suffering from different types of cancer. We are happy to welcome Shire's Oncology team today and join forces continuing pursuing our mission" said Amelie Faubert, Commercial Head, Oncology Business Unit.
Oncology is a key therapeutic area for Servier and its research and development focuses on apoptosis and immuno-oncology. The Group currently devotes 37% of its R&D investments to fighting cancer and addressing critical unmet patient needs. It also has a goal to reach 50% within the next two years. To date, Servier has nineteen strategic research alliances in oncology, including five with American partners, to accelerate patient's access to innovative therapies. This has led to thirteen innovative anti-cancer products in clinical development.
About Servier Canada Servier Canada was established in 1978 and is celebrating its 40th anniversary of operation in Canada. Servier Canada employs over 250 people across Canada and is currently marketing medicines in oncology, diabetes and cardiovascular disease. For additional information please visit our website at www.servier.ca
About Servier Group Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,700 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
SOURCE Servier Canada Inc.
For further information: Media relations: Nadine DOUCET, (Office) 450-978-9700, ext. 4225, (Cell) 514-601-4881, [email protected] Website: www.servier.ca